-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Genmab, Raises Price Target to $40

Benzinga·07/02/2026 11:05:45
Listen to the news
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Genmab (NASDAQ:GMAB) with a Buy and raises the price target from $38 to $40.